An Indiana biotech pioneer developing novel therapeutics for untreatable diseases by targeting multiprotein complexes with proprietary small molecule modulators that restore cellular homeostasis and combat infectious diseases.
Pioneering Biotechnology
Modulant Biosciences, based in Indiana, is transforming animal health through innovative drug discovery. We develop first-in-class therapeutics for previously untreatable infectious and chronic diseases, expanding the frontiers of pharmaceutical possibilities.
Targeting Multiprotein Complexes
Our unique approach targets the disruption of aberrant multiprotein complexes that form when viruses and xenobiotics hijack normal cellular assembly mechanisms, subverting host immunity.
Proprietary Biochemical Tools
Using proprietary biochemical tools, we've discovered small molecules that restore corrupted assembly machines to their normal function, reestablishing cellular homeostasis. This breakthrough methodology offers new hope for conditions that have long resisted conventional treatment approaches.
Our Mission
To discover and develop novel, small molecule allosteric modulators that restore homeostasis and combat infectious diseases.
Our Science
Modulant's proprietary platform targets aberrant multiprotein complexes with small molecule allosteric modulators that restore cellular homeostasis, prevent pathogen subversion of host immunity, and address chronic diseases by reestablishing normal protein assembly dynamics.
At Modulant, we pioneer innovative approaches that work with the body's natural systems rather than against them, using our deep understanding of protein assembly mechanisms to develop transformative therapeutics.
Restoring Cellular Homeostasis
Our allosteric modulators target specific binding sites on multiprotein complexes, correcting aberrant assembly patterns and reinforcing the body's regulatory mechanisms that maintain cellular equilibrium and prevent disease progression.
Preventing Viral Hijacking
Our proprietary small molecules interrupt the protein-protein interactions that viruses exploit to commandeer cellular machinery, effectively blocking viral replication without triggering resistance mechanisms seen with traditional antivirals.
Addressing Chronic Conditions
We apply our multiprotein complex targeting approach to conditions like cancer and inflammatory diseases where cellular signaling pathways have been fundamentally disrupted, restoring normal cellular communication and function.
Pipeline
Modulant's pipeline targets high-impact veterinary diseases through proprietary allosteric modulation technology, focusing on feline infectious diseases, canine cancer, and swine respiratory illness.
Our therapeutic development program addresses critical unmet needs across companion and livestock animals with targeted, innovative solutions:
Feline Therapeutics
Pioneering breakthrough treatments for Feline Infectious Peritonitis (FIP) and Feline Leukemia Virus (FelV), filling significant gaps in veterinary medicine for these previously untreatable conditions.
Canine Oncology
Revolutionizing cancer treatment with our "One Drug for All Cancers" platform, targeting fundamental cellular mechanisms to restore homeostasis across multiple canine cancer types with a single therapeutic approach.
Swine Health Solutions
Developing novel therapeutics against Porcine Reproductive and Respiratory Syndrome (PRRS), addressing a devastating disease that causes billions in annual economic losses to the global livestock industry.
Each program harnesses our proprietary allosteric modulation technology platform, restoring normal cellular function while avoiding the development of treatment resistance that plagues conventional approaches.
Why Modulant
Modulant pioneers a revolutionary antiviral approach by uniquely targeting host cellular functions rather than viruses directly. This proprietary mechanism represents a significant market advancement with no competing compounds in development.
Modulant's revolutionary approach fundamentally distinguishes us in the antiviral landscape:
Our Unique Approach
Unlike conventional treatments, we specifically target host cellular functions that viruses critically depend on for their assembly and replication, establishing an entirely new therapeutic paradigm.
Market Leadership
This groundbreaking strategy represents a significant advancement in antiviral development that NO OTHER COMPOUNDS CURRENTLY ACHIEVE in the market or research pipeline.
Scientific Validation
Our extensive analysis of all documented antivirals confirms that until now, no compounds have successfully modulated these essential host cellular mechanisms. Modulant has pioneered this approach and secured it as our proprietary mechanism of action.
Contact
Ready to explore how Modulant Biosciences can revolutionize veterinary medicine? We welcome your inquiries about our innovative therapeutic solutions.
With extensive experience in biotechnology and pharmaceutical development, Tom leads Modulant's mission to transform animal health through groundbreaking allosteric modulation technology.
Publications
Evaluation of Safety and Pharmacokinetics for Orally Administered MAV-104 in Domestic Shorthair Cats
Efficacy of Oral MAV-104 in Treating Feline Infectious Peritonitis: a Prospective Observational Study of 8 Cats
Modulant Biosciences